Cisplatin versus cisplatin plus D-Trp-6-LHRH in the treatment of ovarian cancer: A pilot trial to investigate the effect of the addition of a GnRH analogue to cisplatin

Oncology (Switzerland)

Volumn 53, Issue 4, 1996, Pages 313-317

  Falkson, Carla I ^a   Falkson, Hendé C ^a   Falkson, Geoffrey ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Cisplatin; Decapeptyl; GnRH analogue; Ovary

Indexed keywords

CISPLATIN; TRIPTORELIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HOT FLUSH; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LEUKOPENIA; NAUSEA; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PILOT PROJECTS; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TRIPTORELIN;

EID: 0029929085     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227579     Document Type: Article

References (14)

1. Biskind MS, Biskind GS: Development of tumors in the rat ovary after transplantation into the spleen, Proc Soc Exp Biol Med 1944:55: 176-179.
2. Pour PM, Redding TW, Paz-Bouza JI, Schally AV: Treatment of experimental ovarian carcinoma with monthly injections of the agonist D-Trp-6-LH-RH: A preliminary report, Cancer Lett 1988:1:105-110.
3. Parmar H, Nicoll J, Stockdalc A, Cassoni A, Phillips RH, Lightman SL, Schally AV: Advanced ovarian carcinoma: Response to the agonist 7)-Trp-6-LHRH, Cancer Treat Rep 1985;96:1341-1342.
4. Parmar H, Phillips RH, Rustin G, Hanham IW, Lightman SL, Schally AV: Response to D-Trp-6-luteinizing hormone releasing hormone (decapeptyl) microcapsules in advanced ovarian cancer, BrJ Med 1988:296:1229.
5. Oken MM, Creech RH, Tormey DC: Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol 1982:5: 649-655.
6. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations, J Am Stat Assoc 1958;53:457-481.
7. Nillius SJ, Bcrgquist C, Wide L: Inhibition of ovulation in women by chronic treatment with a stimulatory LHRH-analogue - A new approach to birth control? Contraception 1978: 17:537-545.
8. Maynard PV, Nicholson RI: Effects of high doses of a scries of new luteinizing hormone-releasing hormone analogues in intact female rats, BrJ Cancer 1979;39:274-279.
9. Schally AV, Coy DH, Arimura A: LHRH agonists and antagonists, Int Gynaecol Obstet 1980;18:318-324.
10. Parmar H, Phillips RH, Lightman SL, Edwards L, Allen L, Schally AV: Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma, Lancet 1985;ii: 1201-1205.
11. Falkson G, Falkson HC: CAF and nasal buserc-lin in the treatment of premenopausal women with metastatic breast cancer, Eur J Cancer Clin Oncol 1989;25:737-741.
12. Jäger W, Wildt L, Lang N: Some observations on the effect of a GnRH analog in ovarian cancer, Eur J Obstet Reprod Biol 1989:32:137-148.
13. Kavanagh JJ, Roberts W, Townsend P, Hewitt S: Leuprolidc acetate in the treatment of refractory or persistent epithelial ovarian cancer, J Cli’n Oncol 1989:7:115-118.
14. Erickson LD, Hartmann LC, Su JQ, Nielsen SNJ, Pfcifcl DM, Goldberg RM, Levitt R, Stanhope CR: Cyclophosphamide, cisplatin, and leuprolidc acetate in patients with debulked stage III or IV ovarian carcinoma, Gynecol Oncol 1994;54:196-200.